Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 16/20 | 0.76 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.76 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.76 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.70 |
| ▸ | CCNC | P24863 | 4/20 | 0.63 |
| ▸ | CDK8 | P49336 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051977 | 0.86 | SELE (1.00) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL5555033 | 0.83 | MAP3K8 (1.00) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL5550720 | 0.82 | MAP3K8 (0.70) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL5550724 | 0.78 | CCNC (0.66) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL7057307 | 0.77 | CCNC (1.00) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL7055471 | 0.77 | CCNC (0.79) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL5550764 | 0.77 | MAP3K8 (0.71) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL7055228 | 0.76 | ICAM1 (0.77) | SELEICAM1VCAM1MAP3K8CCNC | |
| SCHEMBL7057899 | 0.76 | ICAM1 (1.00) | SELEICAM1VCAM1CCNCCDK8 | |
| SCHEMBL7055724 | 0.76 | CCNC (0.79) | SELEICAM1VCAM1MAP3K8CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | SELE 4256/4885ICAM1 4375/4885VCAM1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.